Mettens Pascal, Dubois Patrice M, Demoitié Marie-Ange, Bayat Babak, Donner Marie-Noëlle, Bourguignon Patricia, Stewart V Ann, Heppner D Gray, Garçon Nathalie, Cohen Joe
GlaxoSmithKline Biologicals, Rixensart, Belgium.
Vaccine. 2008 Feb 20;26(8):1072-82. doi: 10.1016/j.vaccine.2007.12.018. Epub 2008 Jan 7.
Protection against Plasmodium falciparum sporozoite infection can be achieved by vaccination with the recombinant circumsporozoite protein-based vaccine RTS,S formulated with the AS02A Adjuvant System. Since this protection is only partial and wanes over time, we have developed a new RTS,S-based vaccine adjuvanted with AS01B. RTS,S/AS01B-induced high specific antibody titers and increased the frequency of mouse CD4(+) and CD8(+) T cells expressing IFN-gamma, and of monkey CD4(+) T cells expressing IL-2 and/or IFN-gamma and/or TNF-alpha upon stimulation with vaccine antigens. Our data provides clear evidence that combining RTS,S antigen with a potent adjuvant induces strong humoral and cellular responses in vivo.
通过接种基于重组环子孢子蛋白的疫苗RTS,S（与AS02A佐剂系统配制），可实现对恶性疟原虫子孢子感染的防护。由于这种防护只是部分的且会随时间减弱，我们研发了一种新的以RTS,S为基础并佐以AS01B的疫苗。RTS,S/AS01B诱导产生高特异性抗体滴度，并增加了在疫苗抗原刺激下表达γ干扰素的小鼠CD4(+)和CD8(+) T细胞，以及表达白细胞介素-2和/或γ干扰素和/或肿瘤坏死因子-α的猴CD4(+) T细胞的频率。我们的数据提供了明确证据，表明将RTS,S抗原与强效佐剂相结合可在体内诱导强烈的体液和细胞免疫反应。
